.webp)
Super-ADCs
for Safer Cancer Therapies
At BioLoomics, we engineer Antibody Drug Conjugates (ADCs) with peptides that enhance payload delivery beyond the limitations of traditional ADCs
Super-ADCs
We add membrane binding peptides to the antibody component of ADCs. This innovation enhances membrane loading and internalization to increase payload release
Learn More
Therapeutic Programs
Where traditional ADCs have fallen short, we aim to deliver best-in-class therapeutics against clinically validated targets in oncology
Learn More
Directed Evolution
We leverage advanced bioinformatics and AI to create libraries of millions of peptide designs that are each tested using our high throughput wet-lab process. This discovery engine optimizes ADCs for membrane loading, internalization, and target specific cytotoxicity
Learn More
About Us
Removing the Boundaries of Traditional ADCs
We are passionate team on a mission to unlock the full potential of ADCs to improve the lives of patients
Meet Our TeamLatest News
BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs
Former CSO of Trilo Therapeutics and Research Fellow atAbbVie joins to lead BioLoomics’ pipeline and combine lysosome targetingantibodies with ADCs
January 29, 2025
BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies
Our mission is to make safer, more effective cancer therapeutics.
January 29, 2025
Backed by former Google CEO’s VC, a Colorado biotech hatches platform to evolve degraders
BioLoomics’ goal is to make a degrader from an antibody in one month
January 29, 2025
